Literature DB >> 28943827

Levofloxacin Use in the Neonate: A Case Series.

Brandi D Newby, Kathryn E Timberlake, Lyndsay M Lepp, Tamara Mihic, Deonne A Dersch-Mills.   

Abstract

We report 6 cases of intravenous levofloxacin use to treat multidrug-resistant nosocomial respiratory infections in neonates with a postmenstrual age ranging from 27 to 42 weeks. Because of a lack of neonatal-specific information for levofloxacin, the usual pediatric dosage (10 mg/kg per dose every 12 hours) was used in these patients. Clinical cure occurred in 5 of the 6 patients. Only minimal short-term adverse effects were noted.

Entities:  

Keywords:  infant; levofloxacin; multidrug-resistant infection; neonate; newborn

Year:  2017        PMID： 28943827      PMCID： PMC5562212          DOI： 10.5863/1551-6776-22.4.304

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN： 1551-6776


  25 in total

1.  Fluoroquinolones and risk of Achilles tendon disorders: case-control study.

Authors:  P D van der Linden; M C J M Sturkenboom; R M C Herings; H G M Leufkens; B H Ch Stricker
Journal:  BMJ       Date:  2002-06-01

2.  The use of systemic and topical fluoroquinolones.

Authors:  John S Bradley; Mary Anne Jackson
Journal:  Pediatrics       Date:  2011-09-26       Impact factor: 7.124

3.  Validation of a dosage individualization table for extended-interval gentamicin in neonates.

Authors:  Deonne Dersch-Mills; Albert Akierman; Belal Alshaikh; Kamran Yusuf
Journal:  Ann Pharmacother       Date:  2012-06-26       Impact factor: 3.154

Review 4.  Ciprofloxacin use in neonates: a systematic review of the literature.

Authors:  Florentia Kaguelidou; Mark A Turner; Imti Choonara; Evelyne Jacqz-Aigrain
Journal:  Pediatr Infect Dis J       Date:  2011-02       Impact factor: 2.129

5.  Risk factors and clinical characteristics of Stenotrophomonas maltophilia infections in neonates.

Authors:  Mehmet Mutlu; Gürdal Yılmaz; Yakup Aslan; Gülçin Bayramoğlu
Journal:  J Microbiol Immunol Infect       Date:  2011-05-24       Impact factor: 4.399

6.  Improving medicines for children in Canada. Findings of the expert panel on therapeutic products for infants, children and youth.

Authors:  Gideon Koren
Journal:  J Popul Ther Clin Pharmacol       Date:  2013-12-01

Review 7.  The clinical pharmacokinetics of levofloxacin.

Authors:  D N Fish; A T Chow
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

8.  Levofloxacin pharmacokinetics in children.

Authors:  Shuchean Chien; Thomas G Wells; Jeffrey L Blumer; Gregory L Kearns; John S Bradley; Joseph A Bocchini; Jaya Natarajan; Samuel Maldonado; Gary J Noel
Journal:  J Clin Pharmacol       Date:  2005-02       Impact factor: 3.126

9.  Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.

Authors:  Fang Li; Partha Nandy; Shuchean Chien; Gary J Noel; Christoffer W Tornoe
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

10.  Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001).

Authors:  Jeffrey T Kirby; Helio S Sader; Timothy R Walsh; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948
View more
  3 in total

1.  Intravenous Ceftazidime-Avibactam in Extremely Premature Neonates With Carbapenem-Resistant Enterobacteriaceae: Two Case Reports.

Authors:  Suzan S Asfour; Faisal A Alaklobi; Adli Abdelrahim; Muhammed Y Taha; Raneem S Asfour; Thanaa M Khalil; Mountasser M Al-Mouqdad
Journal:  J Pediatr Pharmacol Ther       Date:  2022-02-09

2.  High Direct Bilirubin Associated With Levoffoxacin Use in a Neonate.

Authors:  Amy P Holmes; Charles E Hartis; Laurie J Rollins
Journal:  J Pediatr Pharmacol Ther       Date:  2020 Jan-Feb

3.  Emerging Infection with Elizabethkingia Meningoseptica in Neonate. A Case Report.

Authors:  Manuela Arbune; Silvia Fotea; Aurel Nechita; Victorita Stefanescu
Journal:  J Crit Care Med (Targu Mures)       Date:  2018-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.